Payment overview · 2025
General Payments
$518.07
20 reported records · 10 companies
Healthcare provider profile · identity verified
Marcel Abel Bavoux, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · JOHNSTON, RI · NPI 1508990557
Verified facts
What the public records show
CMS Open Payments records show Marcel Abel Bavoux, D.O. received $518.07 in general payments during 2025 across 20 reported records.
ABBVIE INC. accounted for 33.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $174.69 | 33.7% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $76.78 | 14.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $68.46 | 13.2% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $38.70 | 7.5% | 2 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $33.60 | 6.5% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $28.41 | 5.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $27.31 | 5.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $27.02 | 5.2% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $25.60 | 4.9% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $17.50 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $518.07 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $153.86 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $52.29 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $52.25 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $37.63 | 3 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $33.60 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $28.41 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $27.31 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $27.02 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $25.60 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $24.53 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $21.57 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $21.57 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $20.83 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 43 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
43 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 179 | 59 |
| Atorvastatin Calcium | Atorvastatin Calcium | 177 | 71 |
| Amlodipine Besylate | Amlodipine Besylate | 168 | 58 |
| Gabapentin | Gabapentin | 144 | 56 |
| Metformin Hcl | Metformin Hcl | 124 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 112 | 45 |
| Furosemide | Furosemide | 86 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 27 |
| Montelukast Sodium | Montelukast Sodium | 65 | 19 |
| Levothyroxine Sodium | Levothyroxine Sodium | 56 | 16 |
| Ibuprofen | Ibuprofen | 53 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 19 |
| Jardiance | Empagliflozin | 52 | 12 |
| Losartan Potassium | Losartan Potassium | 52 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 47 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 44 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 43 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 41 | 11 |
| Glipizide | Glipizide | 41 | 14 |
| Prednisone | Prednisone | 41 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 40 | 17 |
| Omeprazole | Omeprazole | 40 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 38 | 14 |
| Carvedilol | Carvedilol | 37 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 33 | 12 |
| Trazodone Hcl | Trazodone Hcl | 32 | 15 |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 23 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 30 | 26 |
| Eliquis | Apixaban | 30 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 29 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 24 |
| Meloxicam | Meloxicam | 27 | 11 |
| Topiramate | Topiramate | 27 | suppressed |
| Mupirocin | Mupirocin | 26 | 20 |
| Tramadol Hcl | Tramadol Hcl | 25 | 22 |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Famotidine | Famotidine | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | 12 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Roflumilast | Roflumilast | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 12 |
| Linzess | Linaclotide | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | 11 |
| Fluconazole | Fluconazole | 12 | 11 |
| Lidocaine | Lidocaine | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Allopurinol | Allopurinol | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $518.07 · 20 records | ABBVIE INC. | AIRSUPRA, AREXVY, BREZTRI, Cologuard Collection Kit, EVENITY, GEMTESA, QULIPTA, REXULTI, SHINGRIX, TONMYA, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, XYOSTED, ZORYVE | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error